Media headlines about GlaxoSmithKline (NYSE:GSK) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlaxoSmithKline earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news articles about the pharmaceutical company an impact score of 45.8033874813924 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- GlaxoSmithKline plc (GSK) Raises Dividend to $0.63 Per Share (americanbankingnews.com)
- GlaxoSmithKline’s Revenues in 4Q17 Rose 1% Year-over-Year (finance.yahoo.com)
- GlaxoSmithKline (GSK) Stock Rating Reaffirmed by Cowen (americanbankingnews.com)
- Early Moves to Watch: GlaxoSmithKline plc (NYSE: GSK) – Alpha Beta Stock (alphabetastock.com)
- Dodge & Cox Comments on GlaxoSmithKline (finance.yahoo.com)
A number of equities research analysts recently weighed in on the company. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. TheStreet lowered GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Kepler Capital Markets upgraded GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday, February 9th. Cowen restated a “hold” rating and set a $40.00 price objective on shares of GlaxoSmithKline in a research report on Thursday. Finally, Investec lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.97.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The firm had revenue of $10.14 billion for the quarter, compared to analyst estimates of $9.89 billion. analysts forecast that GlaxoSmithKline will post 2.85 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be given a $0.633 dividend. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.72%. The ex-dividend date is Thursday, February 22nd. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s payout ratio is 234.48%.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.